Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1997 3
1998 2
1999 3
2000 3
2001 2
2002 1
2003 2
2004 1
2005 1
2007 3
2008 2
2009 3
2010 7
2011 5
2012 7
2013 10
2014 8
2015 13
2016 9
2017 16
2018 16
2019 23
2020 15
2021 16
2022 7
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Among authors: schaap n. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA. Harrison CN, et al. Among authors: schaap n. Am J Hematol. 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32129512 Free PMC article. Clinical Trial.
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Harrison CN, et al. Among authors: schaap n. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. Lancet Haematol. 2017. PMID: 28602585 Free PMC article. Clinical Trial.
Stem cell transplantation.
Schaap N. Schaap N. Hemasphere. 2019 Jun 30;3(Suppl):163. doi: 10.1097/HS9.0000000000000266. eCollection 2019 Jun. Hemasphere. 2019. PMID: 35309765 Free PMC article. No abstract available.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Immunotherapeutic approaches to treat multiple myeloma.
Roeven MW, Hobo W, Schaap N, Dolstra H. Roeven MW, et al. Among authors: schaap n. Hum Vaccin Immunother. 2014;10(4):896-910. doi: 10.4161/hv.27380. Epub 2013 Dec 11. Hum Vaccin Immunother. 2014. PMID: 24335570 Free PMC article. Review.
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge PKJD, Evert JSH, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H. Van der Meer JMR, et al. Among authors: schaap npm. Cancer Immunol Immunother. 2021 May;70(5):1305-1321. doi: 10.1007/s00262-020-02749-8. Epub 2020 Nov 3. Cancer Immunol Immunother. 2021. PMID: 33140189 Free PMC article.
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Zhang J, Sy O, Mesa RA. Harrison CN, et al. Among authors: schaap n. Br J Haematol. 2022 Jul;198(2):317-327. doi: 10.1111/bjh.18207. Epub 2022 Apr 27. Br J Haematol. 2022. PMID: 35476316 Free PMC article. Clinical Trial.
Thalidomide and lenalidomide in primary myelofibrosis.
Holle N, de Witte T, Mandigers C, Schaap N, Raymakers R. Holle N, et al. Among authors: schaap n. Neth J Med. 2010 Aug;68(1):293-8. Neth J Med. 2010. PMID: 20739725 Free article. Review.
159 results